Date: 2015-12-03
Type of information: Nomination
Compound:
Company: BiolineRx (Israel)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 3, 2015, BioLineRx reported the establishment of a Scientific Advisory Board (SAB) to provide insight and guidance on the Company’s activities in the field of oncology. The members of BioLineRx’s SAB include four renowned clinicians and translational scientists in oncology. These include: Professor Aaron Ciechanover, Ph.D., M.D., Head of Tumor and Vascular Biology Research Center, the Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology; Jorge Eduardo Cortes, M.D., Professor of Medicine and Deputy Chair, and Chief of the CML Section of the Department of Leukemia at The University of Texas, MD Anderson Cancer; Debasish Roychowdhury, M.D., President, Nirvan Consultants, LLC; and Prof. Yosef Yarden, Ph.D., the Harold and Zeda Goldenberg Chair of Molecular Cell Biology at the Weizmann Institute of Science, Israel.
Professor Aaron Ciechanover is currently a Distinguished Research Professor at the Rappaport Faculty of Medicine of the Technion-Israel Institute of Technology, and the co-Director of the Technion Integrated Cancer Center (TICC). Prof. Ciechanover shared the 2004 Nobel Prize in Chemistry with Professors Avram Hershko and Irwin Rose, for the discovery of ubiquitin-mediated protein degradation. Prof. Ciechanover also received the 2000 Albert Lasker Award and the 2003 Israel Prize.
Dr. Cortes is Professor of Medicine and Deputy Chair, and is also the Chief of the CML and AML Sections of the Department of Leukemia at The University of Texas, MD Anderson Cancer Center. Dr. Cortes’ clinical interests focus on new drug development and the management of patients with myelodysplastic syndromes, acute and chronic leukemia, and myeloproliferative neoplasms. Dr. Cortes has authored hundreds of peer-reviewed manuscripts, abstracts, book chapters, and other medical publications. He is an associate editor for Blood and serves on the editorial board of other journals such as Journal of Clinical Oncology, American Journal of Hematology and Clinical Cancer Research. In addition, Dr. Cortes serves on the Board of the International CML Foundation.
Dr. Roychowdhury is a leader in the pharmaceutical industry with a strong background in oncology research and development, and regulatory and commercial operations, having previously served in key senior leadership roles at Sanofi, GSK and Eli Lilly. Dr. Roychowdhury played a key role in the development and advancement of Seragon’s selective estrogen receptor degraders (SERDs) platform for breast cancer and other hormone-driven cancers. Dr. Roychowdhury has a distinguished track record in the field of oncology having been involved in the approval of nine oncology drugs, including Almita, Tykerb and Jevtana. Currently, he is President of Nirvan Consultants, LLC and in this capacity he serves in senior advisory roles for biotechnology companies to help advance their pipeline of therapeutics.
Prof. Yosef Yarden is The Harold and Zeda Goldenberg Chair of Molecular Cell Biology at the Weizmann Institute of Science, Israel. Professor Yarden’s research focuses on tumor progression and strategies to block cancer using molecular targeted therapies. He served as Chair of the Research Committee of the Israel Cancer Association, President of the Federations of Israeli Societies of Experimental Biology, and Chair of the Israel National Committee on Biotechnology, an advisory body of the Government of the State of Israel. His past administrative responsibilities at the Weizmann Institute include Dean of the Faculty of Biology, Vice-President for Academic Affairs, first Director of the M.D. Moross Institute for Cancer Research, and Dean of the Feinberg Graduate School.
Financial terms:
Latest news:
